Key facts
- Truvian’s last known valuation is $329.0M.
- It has raised $294.4M; the latest was Later Stage VC ($74.0M) in Jul 2024.
- Notable investors include General Catalyst, CONNECT(San Diego), GreatPoint Ventures, DNS Capital, Tao Capital Partners — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Truvian
- ·The full record, as it builds
Funding rounds
No funding rounds for Truvian are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Truvian
Developer of an automated blood testing and diagnostic technology designed to deliver a convenient and affordable alternative to off-site labs. The company's technology combines clinical chemistries, immunoassays, and hematology assays all within one instrument, in a single run and provides lab-accurate results in less time for a suite of health tests, enabling healthcare professionals to get access to comprehensive, easy-to-understand lab test reports and insights while also making routine health testing suitable and reasonable.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2015
- Employees
- 119
- Website
- truvianhealth.com/
- Ownership
- Privately Held (backing)
Truvian doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Truvian shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Truvian in its N-PORT filings yet. We sweep new filings monthly.